Financing 806 Views SynAct resolves on a fully guaranteed rights issue of 150 MSEK Malin Otmani March 28, 2022 The Board of Directors of …
Clinical Trials 1339 Views SynAct Pharma’s AP1189 meets primary endpoint Malin Otmani November 30, 2021 SynAct Pharma has announced results …
Clinical Trials 791 Views SynAct completes patient recruitment to Phase 2a study Malin Otmani September 24, 2021 SynAct Pharma completes patient recruitment …
In a new job 2218 Views SynAct appoints Vice President Finance and Director of Operational R&D Malin Otmani August 16, 2021 The company has announced the …
COVID-19 2632 Views SynAct Pharma announces positive additional trial data Malin Otmani July 28, 2021 SynAct Pharma has announced additional …
Clinical Trials 1288 Views SynAct Pharma announces Phase 2 data Malin Otmani November 15, 2020 SynAct Pharma has announced that …
COVID-19 1187 Views SynAct Pharma initiates study for the treatment of ARDS in COVID-19 patients Malin Otmani September 24, 2020 SynAct Pharma has announced the …
COVID-19 2885 Views SynAct investigates AP1189 as additional therapy in hospitalized patients with COVID-19 Malin Otmani March 31, 2020 SynAct Pharma investigates the possibility …
